UY24482A1 - Quinoxalinadionas - Google Patents
QuinoxalinadionasInfo
- Publication number
- UY24482A1 UY24482A1 UY24482A UY24482A UY24482A1 UY 24482 A1 UY24482 A1 UY 24482A1 UY 24482 A UY24482 A UY 24482A UY 24482 A UY24482 A UY 24482A UY 24482 A1 UY24482 A1 UY 24482A1
- Authority
- UY
- Uruguay
- Prior art keywords
- ring
- quinoxalinadione
- group containing
- attached
- heteroaryl group
- Prior art date
Links
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Luminescent Compositions (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
Abstract
La invención se refiere a derivados de 5-heteroaril-2,3 (1H,4H)-quinoxalinadiona de la fórmula (I), en la que: R es un grupo heteroarilo de anillo de 5 miembros que contiene 3 ó 4 heteroátomos de nitrógeno, que está unido al anillo de quinoxalinadiona mediante un átomo de carbono o nitrógeno del anillo, o es un grupo heteroarilo de anillo de 6 miembros que contiene de 1 a 3 heteroátomos de nitrógeno, que está unido al anillo de quinoxalinadiona por un átomo de carbono del anillo; R1 y R2 se seleccionan cada uno, independientemente, entre H y alquilo o, cuando se toman conjuntamente, son alquileno; y las sales farmacéuticamente aceptables de los mismos. Dichos compuestos son útiles como antagonistas de receptores NMDA (N-metil-D-aspartato) para el tratamiento de transtornos neurodegenerativos agudos y transtornos neurológicos crónicos. Ej. no limitante: R-(-)-6,7-dicloro-5-[3-metoximetil-5-(3-piridil)-4H-1,2,4-triazol-4-il]-2,3 (1H,4H)-quinoxalinadiona.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9605027.3A GB9605027D0 (en) | 1996-03-09 | 1996-03-09 | Quinoxalinediones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY24482A1 true UY24482A1 (es) | 2000-09-29 |
Family
ID=10790134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY24482A UY24482A1 (es) | 1996-03-09 | 1997-03-06 | Quinoxalinadionas |
Country Status (42)
| Country | Link |
|---|---|
| US (1) | US6376490B1 (es) |
| EP (1) | EP0885212B1 (es) |
| JP (1) | JP3110467B2 (es) |
| KR (1) | KR100288099B1 (es) |
| CN (1) | CN1103770C (es) |
| AP (1) | AP767A (es) |
| AR (1) | AR006119A1 (es) |
| AT (1) | ATE208773T1 (es) |
| AU (1) | AU717972B2 (es) |
| BG (1) | BG63340B1 (es) |
| BR (1) | BR9707851A (es) |
| CA (1) | CA2248366C (es) |
| CO (1) | CO4770976A1 (es) |
| CZ (1) | CZ292792B6 (es) |
| DE (1) | DE69708269T2 (es) |
| DK (1) | DK0885212T3 (es) |
| DZ (1) | DZ2188A1 (es) |
| EA (1) | EA001730B1 (es) |
| ES (1) | ES2163742T3 (es) |
| GB (1) | GB9605027D0 (es) |
| HN (1) | HN1998000034A (es) |
| HR (1) | HRP970132A2 (es) |
| HU (1) | HUP9900975A3 (es) |
| ID (1) | ID18112A (es) |
| IL (1) | IL125491A (es) |
| IS (1) | IS4811A (es) |
| MA (1) | MA26422A1 (es) |
| NO (1) | NO984058L (es) |
| NZ (1) | NZ331060A (es) |
| OA (1) | OA10850A (es) |
| PE (2) | PE43398A1 (es) |
| PL (1) | PL329032A1 (es) |
| PT (1) | PT885212E (es) |
| SI (1) | SI0885212T1 (es) |
| SK (1) | SK283467B6 (es) |
| TN (1) | TNSN97044A1 (es) |
| TR (1) | TR199801782T2 (es) |
| TW (1) | TW454004B (es) |
| UY (1) | UY24482A1 (es) |
| WO (1) | WO1997032873A1 (es) |
| YU (2) | YU39698A (es) |
| ZA (1) | ZA971987B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP982A (en) * | 1997-02-27 | 2001-07-16 | Pfizer | Quinoxalinediones. |
| JP3588363B2 (ja) * | 1997-02-27 | 2004-11-10 | ファイザー・インク | キノキサリンジオン類 |
| US6340758B1 (en) * | 1997-05-16 | 2002-01-22 | Warner-Lambert Company | Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents |
| DE10005150A1 (de) * | 2000-02-07 | 2001-08-09 | Merck Patent Gmbh | Verfahren zur Herstellung von 5-Arylnicotinaldehyden |
| BR0110961A (pt) * | 2000-05-19 | 2004-06-29 | Merck Patent Gmbh | Derivados de triazol |
| US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
| WO2005006945A2 (en) * | 2003-07-03 | 2005-01-27 | The Salk Institute For Biological Studies | Methods for treating neural disorders and compounds useful therefor |
| MY145368A (en) * | 2004-01-13 | 2012-01-31 | Nissan Chemical Ind Ltd | Aminoquinoxaline compounds and polyaminoquinoxaline compounds, and use thereof |
| EP1713101B1 (en) | 2004-02-06 | 2012-10-31 | Yamaguchi University | Electrode for energy storage device and process for producing the same |
| JP2007223901A (ja) * | 2004-03-24 | 2007-09-06 | Takeda Chem Ind Ltd | 複素環化合物およびその用途 |
| US20060211739A1 (en) * | 2005-02-08 | 2006-09-21 | Arturo Perez-Medrano | Use of selective P2X7 receptor antagonists |
| WO2007112347A1 (en) * | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
| US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| WO2008088820A2 (en) | 2007-01-16 | 2008-07-24 | The Johns Hopkins University | Glutamate receptor antagonists and methods of use |
| CN101668525A (zh) | 2007-03-01 | 2010-03-10 | 前体生物药物股份公司 | 谷氨酰胺酰环化酶抑制剂的新用途 |
| EP2142514B1 (en) | 2007-04-18 | 2014-12-24 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
| CN106928157A (zh) * | 2007-05-17 | 2017-07-07 | 株式会社半导体能源研究所 | 三唑衍生物 |
| SG178953A1 (en) | 2009-09-11 | 2012-04-27 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
| ES2586231T3 (es) | 2010-03-03 | 2016-10-13 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| DK2545047T3 (da) | 2010-03-10 | 2014-07-28 | Probiodrug Ag | Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5) |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
| CA2900300A1 (en) * | 2013-02-07 | 2014-08-14 | Merck Patent Gmbh | Substituted acetylene derivatives and their use as positive allosteric modulators of mglur4 |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
| CN111548320B (zh) * | 2019-10-09 | 2023-03-24 | 贵州大学 | 一类1，3，4-噁二唑酰肼类化合物及其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2550456B2 (ja) * | 1990-11-06 | 1996-11-06 | 山之内製薬株式会社 | 縮合ピラジン誘導体 |
| DE4217952A1 (de) * | 1992-05-30 | 1993-12-02 | Basf Ag | Chinoxalin-2,3(1H,4H)-dione |
| GB9418443D0 (en) | 1994-09-13 | 1994-11-02 | Pfizer Ltd | Therapeutic agents |
| DE4439492A1 (de) * | 1994-10-25 | 1996-05-02 | Schering Ag | Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln |
| JP3588363B2 (ja) * | 1997-02-27 | 2004-11-10 | ファイザー・インク | キノキサリンジオン類 |
-
1996
- 1996-03-09 GB GBGB9605027.3A patent/GB9605027D0/en active Pending
-
1997
- 1997-02-05 TW TW086101412A patent/TW454004B/zh not_active IP Right Cessation
- 1997-02-27 KR KR1019980707063A patent/KR100288099B1/ko not_active IP Right Cessation
- 1997-02-27 WO PCT/EP1997/000995 patent/WO1997032873A1/en active IP Right Grant
- 1997-02-27 AU AU20231/97A patent/AU717972B2/en not_active Ceased
- 1997-02-27 EA EA199800702A patent/EA001730B1/ru not_active IP Right Cessation
- 1997-02-27 CA CA002248366A patent/CA2248366C/en not_active Expired - Fee Related
- 1997-02-27 YU YU39698A patent/YU39698A/sh unknown
- 1997-02-27 IL IL12549197A patent/IL125491A/xx not_active IP Right Cessation
- 1997-02-27 AT AT97908156T patent/ATE208773T1/de not_active IP Right Cessation
- 1997-02-27 SI SI9730225T patent/SI0885212T1/xx unknown
- 1997-02-27 CN CN97192923A patent/CN1103770C/zh not_active Expired - Fee Related
- 1997-02-27 CZ CZ19982864A patent/CZ292792B6/cs not_active IP Right Cessation
- 1997-02-27 DE DE69708269T patent/DE69708269T2/de not_active Expired - Fee Related
- 1997-02-27 PT PT97908156T patent/PT885212E/pt unknown
- 1997-02-27 SK SK1214-98A patent/SK283467B6/sk unknown
- 1997-02-27 BR BR9707851A patent/BR9707851A/pt not_active Application Discontinuation
- 1997-02-27 EP EP97908156A patent/EP0885212B1/en not_active Expired - Lifetime
- 1997-02-27 HU HU9900975A patent/HUP9900975A3/hu unknown
- 1997-02-27 JP JP09531429A patent/JP3110467B2/ja not_active Expired - Fee Related
- 1997-02-27 PL PL97329032A patent/PL329032A1/xx unknown
- 1997-02-27 NZ NZ331060A patent/NZ331060A/xx unknown
- 1997-02-27 ES ES97908156T patent/ES2163742T3/es not_active Expired - Lifetime
- 1997-02-27 DK DK97908156T patent/DK0885212T3/da active
- 1997-02-27 TR TR1998/01782T patent/TR199801782T2/xx unknown
- 1997-03-05 TN TNTNSN97044A patent/TNSN97044A1/fr unknown
- 1997-03-05 DZ DZ970034A patent/DZ2188A1/fr active
- 1997-03-05 AR ARP970100888A patent/AR006119A1/es unknown
- 1997-03-05 MA MA24514A patent/MA26422A1/fr unknown
- 1997-03-06 PE PE1997000162A patent/PE43398A1/es not_active Application Discontinuation
- 1997-03-06 UY UY24482A patent/UY24482A1/es not_active IP Right Cessation
- 1997-03-06 AP APAP/P/1997/000947A patent/AP767A/en active
- 1997-03-07 ID IDP970725A patent/ID18112A/id unknown
- 1997-03-07 ZA ZA971987A patent/ZA971987B/xx unknown
- 1997-03-07 HR HR9605027.3A patent/HRP970132A2/xx not_active Application Discontinuation
- 1997-03-10 CO CO97012901A patent/CO4770976A1/es unknown
-
1998
- 1998-02-19 HN HN1998000034A patent/HN1998000034A/es unknown
- 1998-02-23 PE PE1998000128A patent/PE58199A1/es not_active Application Discontinuation
- 1998-02-24 YU YU41199A patent/YU41199A/sh unknown
- 1998-07-27 IS IS4811A patent/IS4811A/is unknown
- 1998-08-28 OA OA9800155A patent/OA10850A/en unknown
- 1998-09-03 NO NO984058A patent/NO984058L/no unknown
- 1998-09-04 US US09/157,806 patent/US6376490B1/en not_active Expired - Fee Related
- 1998-09-09 BG BG102760A patent/BG63340B1/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY24482A1 (es) | Quinoxalinadionas | |
| EA200000592A1 (ru) | Азаполициклические соединения, конденсированные с арилом | |
| ES2111650T3 (es) | Derivados aciclicos de etilenodiamina como antagonistas de receptores de la sustancia p. | |
| PA8431301A1 (es) | Inhibidores de metaloproteinasas, composiciones farmaceuticas que los contienen y sus usos farmaceuticos y los metodos e intermedios utiles para su preparacion | |
| BR0013427A (pt) | Compostos heteropolicìclicos e seus usos como antagonistas no receptor de glutamato metabotrópico | |
| TR199801594A2 (xx) | CCR-3 resept�r antagonistleri. | |
| EA199800404A1 (ru) | Производные 1-(1,2-дизамещенный пиперидинил)-4-замещенного пиперазина | |
| KR930017904A (ko) | 축합 이미다조피리딘 유도체 | |
| EP1256574A4 (en) | COMPOUNDS CONTAINING NITROGEN AND HAVING KINASE INHIBITION ACTIVITY, AND MEDICINAL PRODUCTS COMPRISING SUCH COMPOUNDS | |
| FI954105A (fi) | Uusia 4-aminopyridiinejä, niiden valmistusmenetelmä sekä näitä yhdisteitä sisältäviä lääkkeitä | |
| BR0306208A (pt) | Compostos de dibenzilamina e seu uso farmacêutico | |
| ES2189330T3 (es) | Derivados heterociclicos n6 de la adenosina sustituidos. | |
| UY26086A1 (es) | Procedimientos e intermedios para preparar compuestos anticancerosos | |
| DE3851597D1 (de) | Lactamderivate. | |
| ES2158126T3 (es) | Quinoxalinadionas antagonistas del receptor nmda. | |
| UY25804A1 (es) | Derivados de 4-aroilpiperidina que son antagonistas de los receptores ccr-3 | |
| NO20025641D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
| ES2195933T3 (es) | Nuevos derivados de flavonas, xantonas y cumarinas. | |
| DE69018678D1 (de) | Trizyklische Lactamderivate und pharmazeutische Zusammensetzungen, die sie enthalten. | |
| YU53100A (sh) | Derivati 2-ariletil-(piperidin-4-ilmetil)amina kao antagonisti muskarinskih receptora | |
| PL361282A1 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
| BR0215017A (pt) | Lactamas como antagonistas da taquiquinina | |
| AR015446A1 (es) | Antagonistas de receptores de vitronectina, composicion farmaceutica que los contiene, procedimiento para su preparacion, su uso para la elaboracion de unmedicamento y compuestos intermediarios | |
| MX2007011280A (es) | Dipirazoles como farmacos del sistema nervioso central. | |
| AR068381A1 (es) | Compuestos de quinolina apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| VENC | Patent expired |
Effective date: 20170306 |